Cardiac Management of Patients With Thalassemia Minor and Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This retrospective study aimed to evaluate the demographic characteristics, clinical conditions in term of physical examination findings), functional status, and laboratory results of patients with thalassemia minor (TM) and breast cancer (BC) in order to identify any differences between the group with BC only. Available data as anticancer treatment, comorbidities, weight and height will be combined to report body mass index (BMI) in kg/m2, systolic and diastolic blood pressure, heart rate, ECG, transthoracic echocardiography, blood count, lipid panels, glucose, kidney function tests, (N terminal) NT-proBNP, troponins, handgrip assessments, functional status were extracted from patients files and hospital electronic archives.

Detailed Description
-----------------
Following data was extracted from files and hospital electronic records, and will be evaluated (at baseline, 3, 6, 9 and 12 months): Physical examination findings (as pretibial edema, jugular venous distension, lung rales), Clinically significant changes in cardiac function as determined by Left Ventricular Ejection Fraction (LVEF) measurements using transthoracic echocardiography, Any changes in (N terminal) NT-ProBNP and troponin, Any changes in manual handgrip measurements for both hands using hydraulic hand dynamometer, Applied medications, were extracted and will be evaluated.

Official Title
-----------------
Management of Patients With Thalassemia Minor and Breast Cancer at CardioOncology Outpatient Clinics: Age Quod Agis (AQUA)

Conditions
-----------------
Breast Cancer, Thalassemia Minor, Heart Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with diagnosis of breast cancer, and thalassemia minor, >18 years old, Referred by oncologist for cardiac evaluation. Patients with available cardiac evaluations data at baseline and during breast cancer treatment Exclusion Criteria: Patients without diagnosis of breast cancer, and thalassemia minor, <18 years old, Patients without any cardiac evaluations at baseline, and during cancer treatment. Patients with history of any cardiotoxic treatment prior to enrolment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 13 pts with BC+TM<br>Patients diagnosed with breast cancer and thalassemia minor | |
| 13 pts with BC<br>Patients diagnosed with breast cancer for comparison. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of any rise in troponin | Troponin results from baseline and at 3, 6 and 12 months of cancer treatment . | From enrollment to 12 months | 
| Incidence of any rise in NT-ProBNP | NT-ProBNP results from baseline and at 3, 6 and 12 months of cancer treatment . | From enrollment to 12 months | 
| Incidence of any reduction in LV | Echocardiographic measurements of Left ventricle (LV) ejection fraction from baseline and at 3, 6 and 12 months of cancer treatment. | From enrollment to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiotoxicity, Cancer treatment related cardiac dysfunctions